PTU-44 Colonoscopy and the elderly: should we utilise CT colonoscopy as a first-line test?

A novel group of medications, dual orexin receptor antagonists, emerged as a competent group that challenges current first-line hypnotics. They have relatively infrequent and mostly well-tolerated side effects, primarily in the form of residual somnolence, fatigue and nightmares/disturbing dreams. The advantage over conventional hypnotics stems from the specifics of their target receptors, which translates into lack of tolerance after long term use and good safety profile. They are particularly favoured in some specific populations, including the elderly. Ongoing and future studies are set to explore their effect on selected conditions, such as addiction and psychiatric disorders, dementias, perimenopausal condition and circadian rhythm disorders, to name a few.

Download Full-text

Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment?

Journal of Neuro-Oncology ◽

10.1007/s11060-017-2573-y ◽

2017 ◽

Vol 135 (2) ◽

pp. 285-297 ◽

Cited By ~ 13

Author(s):

Marc Zanello ◽

◽

Alexandre Roux ◽

Renata Ursu ◽

Sophie Peeters ◽

...

Keyword(s):

The Elderly ◽

Line Treatment ◽

Second Line ◽

First Line ◽

First Line Treatment

Download Full-text

SOX10/keratin dual-color immunohistochemistry: An effective first-line test for the workup of epithelioid malignant neoplasms in FNA and small biopsy specimens

Cancer Cytopathology ◽

10.1002/cncy.21960 ◽

2018 ◽

Vol 126 (3) ◽

pp. 179-189 ◽

Cited By ~ 5

Author(s):

Jeffrey K. Mito ◽

James R. Conner ◽

Jason L. Hornick ◽

Edmund S. Cibas ◽

Xiaohua Qian

Keyword(s):

Malignant Neoplasms ◽

First Line ◽

Biopsy Specimens ◽

Dual Color ◽

Line Test

Download Full-text

Diagnostic utility of dual 5‐hydroxymethylcytosine/Melan‐A immunohistochemistry in differentiating nodal nevus from metastatic melanoma: An effective first‐line test for the workup of sentinel lymph node specimen

Journal of Cutaneous Pathology ◽

10.1111/cup.13412 ◽

2019 ◽

Vol 46 (4) ◽

pp. 261-266 ◽

Cited By ~ 2

Author(s):

Andrew B. Siref ◽

Carissa A.T. Huynh ◽

Bonnie L. Balzer ◽

David P. Frishberg ◽

Richard Essner ◽

...

Keyword(s):

Lymph Node ◽

Sentinel Lymph Node ◽

Metastatic Melanoma ◽

Diagnostic Utility ◽

First Line ◽

Line Test

Download Full-text

The Role of Novel Bone Forming Agents in the Treatment of Osteoporosis

Journal of Pharmacy Practice ◽

10.1177/0897190020961227 ◽

2020 ◽

pp. 089719002096122

Author(s):

Hansita B. Patel ◽

Lynsie J. Lyerly ◽

Cheryl K. Horlen

Keyword(s):

Elderly Population ◽

Cost Effective ◽

The Elderly ◽

Bisphosphonate Therapy ◽

Evidence Based ◽

First Line ◽

Treatment Of Osteoporosis ◽

Cost Effective Treatment

Osteoporosis is a growing epidemic that leads to significant morbidity and mortality among the elderly population due to associated fractures that lead to disabilities and reduced quality of life. Bisphosphonates are well-established as a first-line and cost-effective treatment for osteoporosis. Unfortunately, clinicians are often uncertain as to how to select treatments when bisphosphonates are ineffective as initial treatment or contraindicated. Romosozumab and abaloparatide are 2 alternative agents that have been recently FDA approved for the treatment of osteoporosis in postmenopausal women at high risk for fracture or patients who have failed or are intolerant to other osteoporosis therapies. Currently, the National Osteoporosis Foundation (NOF) has no formal recommendations in regard to these 2 novel agents. The purpose of this review is to help guide pharmacists on how to ensure appropriate utilization of these 2 novel bone-forming agents as potential alternatives to bisphosphonate therapy by providing evidence-based recommendations according to the current literature and key counseling points.

Download Full-text

The treatment of bipolar disorder in the elderly

10.1093/med/9780198748625.003.0022 ◽

2017 ◽

Author(s):

Gilberto Sousa Alves ◽

Felipe Kenji Sudo ◽

Johannes Pantel

Keyword(s):

Bipolar Disorder ◽

Gold Standard ◽

Atypical Antipsychotics ◽

Extended Release ◽

Ethical Issues ◽

The Elderly ◽

Evidence Based ◽

Pharmacological Interventions ◽

First Line ◽

Evidence Based Guidelines

Bipolar disorder (BD) is an extremely disabling condition characterized by mood switches, and cognitive and functional impairment. The current chapter discusses the updated review on pharmacological and non-pharmacological interventions targeting BD in the elderly. The risk of concurrent medical diseases (eg, metabolic syndrome) and relatively lower tolerability than young BD make the patient safety a major concern in most cases. Evidence-based guidelines, although useful for promoting rational and effective therapy, are generally lacking in elderly BD. Current recommendations for acute mania include atypical antipsychotics, careful use of lithium, and election of valproate as the gold-standard therapy. In acute BD depression, first-line agents in monotherapy may include lithium, lamotrigine, quetiapine, and quetiapine extended release (XR). Electroconvulsive therapy may be an option for severe/refractory cases. Family members or caregivers should be encouraged to support the patient, since potential ethical issues involving patrimony or profession may arise during the treatment.

Download Full-text